Neurodegenerative Disease
P-tau 217 detects Alzheimer’s pathology in neurodegenerative syndromes
Phosphorylated tau 217 better detected Alzheimer’s disease pathology across a range of neurodegenerative syndromes compared with other plasma blood-based biomarkers, data from a study in JAMA Neurology show.
‘Don’t skip leg day’: Plant-based foods, regular exercise boost brain health
Consuming a diet with more plant-based foods and the right kind of fats while engaging in daily exercise are sure-fire paths to maintaining brain health, according to speakers at the Lifestyle Medicine Conference.
Study: Body composition associated with neurodegenerative disease, brain aging
Body composition patterns associated with weight and fat distribution were strongly correlated with neurodegenerative disease and brain aging, mediated by cardiovascular disease, according to research published in Neurology.
Q&A: Understanding protein dysregulation key to preventing neurodegeneration
Prothena Corp. recently announced it would receive $80 million from Bristol Myers Squibb for an exclusive global license to an investigational therapeutic developed to address protein dysregulation.
FDA grants breakthrough designation to frontotemporal dementia treatment
The FDA has granted breakthrough therapy designation to latozinemab, an investigational therapeutic designed to block sortilin and elevate progranulin to treat frontotemporal dementia with a progranulin gene mutation.
Glial fibrillary acidic protein may identify risk for brain atrophy, cognitive decline
For individuals exposed to athletic-related head contact, glial fibrillary acidic protein may help identify those who are at risk for progressive regional brain atrophy and cognitive decline, per data from Alzheimer’s Research & Therapy.
VIDEO: Importance of predictive genetic testing in people at risk for Huntington’s disease
Healio spoke with Erin Furr Stimming, MD, about risk factors that can be addressed early in Huntington’s disease.
Rapport Therapeutics raises $150M in funding to advance neuromedicine platform
A clinical-stage biotechnology company announced that it has raised $150 million in funding to advance its neuromedicine platform.
JCR Pharmaceuticals, Alexion partner to develop novel neurodegenerative therapy
JCR Pharmaceuticals Co. has entered into an agreement with AstraZeneca’s Rare Disease division, Alexion, to develop a novel therapeutic molecule for the treatment of neurodegenerative disease.
Cardiometabolic multimorbidity impacts dementia risk
Cardiometabolic multimorbidity and midlife onset of cardiometabolic disease are significantly associated with an increased risk for dementia, and genetic background may underlie this association, researchers reported.